Data / Form D filings / Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.: Form D filings
Cellectar Biosciences, Inc., a biotechnology company in Florham Park, NJ, filed 9 Form D notices with the SEC between 2009 and 2023. The latest, on September 22, 2023, reports $24.5 million sold of a $24.5 million offering to 21 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 100 CAMPUS DRIVE, SUITE 207, Florham Park, NJ, 07932
- Phone
- (608) 441-8120
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1279704
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2023 | New notice | $24,500,000 | $24,500,000 | 21 | Sep 8, 2023 | sec.gov | |
| Jan 8, 2021 | New notice | $20,499,993 | $20,499,993 | 16 | Dec 28, 2020 | sec.gov | |
| May 31, 2019 | New notice | $14,645,000 | $5,045,000 | $9,600,000 | 11 | May 20, 2019 | sec.gov |
| Oct 13, 2017 | New notice | $7,766,164 | $7,766,164 | 3 | Oct 12, 2017 | sec.gov | |
| Aug 15, 2014 | New notice | $1,000,000 | $617,500 | $382,500 | 8 | Aug 1, 2014 | sec.gov |
| Apr 14, 2011 | New notice | $5,134,903 | $5,134,903 | 0 | Apr 8, 2011 | sec.gov | |
| Nov 19, 2009 | Amendment | $9,000,000 | $9,000,000 | 1 | Aug 25, 2009 | sec.gov | |
| Sep 9, 2009 | New notice | $9,000,000 | $3,500,000 | $5,500,000 | 1 | Aug 26, 2009 | sec.gov |
| Feb 26, 2009 | New notice | $32,250,000 | $32,250,000 | 12 | Feb 11, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Chad J. Kolean | Executive Officer | |
| Jarrod J. Longcor | Executive Officer | |
| Darrell Shane Lea | Executive Officer | |
| Frederick W. Driscoll | Director | |
| James V. Caruso | Executive Officer, Director | |
| Stefan D. Loren | Director | |
| John D. Neis | Director | |
| Asher Alban Chanan-Kahn | Director | |
| Douglas J. Swirsky | Director | |
| Andrei Shane Shustov | Executive Officer |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Sep 18, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cellectar Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.